Rexahn Pharmaceuticals, Inc. Gains 78.54%

Rexahn Pharmaceuticals, Inc. (REXN:NASDAQ) jumped higher at $3.66, representing a gain of 78.5%. From Tue 21 Jan 20, the stock recorded 42.86% Up Days and 46.67% Green Days

The share price of the company has been moving sideways in recent weeks.

About Rexahn Pharmaceuticals, Inc. (REXN:NASDAQ)

Rexahn Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is dedicated to the discovery, development, and commercialization of treatments for cancer. Its mission is to improve the lives of cancer patients by developing next-generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment. Rexahn has developed three clinical-stage drug candidates: RX-3117, Supinoxin (RX-5902) and Archexin. RX-3117 is a small molecule nucleoside compound with an anti-metabolite mechanism of action.